| SGOL2 promotes prostate cancer progression by inhibiting RAB1A ubiquitination. | SGOL2 promotes prostate cancer progression by inhibiting RAB1A ubiquitination.
Lv T, He D, Zhang X, Guo X, Li Z, Zhang A, Fan B, Wang Z., Free PMC Article | 01/14/2023 |
| High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma. | High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma.
Deng M, Li S, Mei J, Lin W, Zou J, Wei W, Guo R., Free PMC Article | 12/11/2021 |
| Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas. | Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas.
Kao Y, Tsai WC, Chen SH, Hsu SY, Huang LC, Chang CJ, Huang SM, Hueng DY., Free PMC Article | 11/13/2021 |
| results identify an unexpected function of SGO2 in mitotically dividing cells and a mechanism of separase regulation that is independent of securin but still supervised by the spindle assembly checkpoint | Securin-independent regulation of separase by checkpoint-induced shugoshin-MAD2.
Hellmuth S, Gómez-H L, Pendás AM, Stemmann O. | 06/6/2020 |
| The SET localizes at the inner centromere by interacting directly with SGO2, with SET levels declining at increased distances between kinetochore pairs, leading to establishment of chromosome bi-orientation. | Aurora B kinase activity is regulated by SET/TAF1 on Sgo2 at the inner centromere.
Asai Y, Fukuchi K, Tanno Y, Koitabashi-Kiyozuka S, Kiyozuka T, Noda Y, Matsumura R, Koizumi T, Watanabe A, Nagata K, Watanabe Y, Terada Y., Free PMC Article | 05/16/2020 |
| Results from a study on gene expression variability markers in early-stage human embryos shows that SGO2 is a putative expression variability marker for the 3-day, 8-cell embryo stage. | Variability of Gene Expression Identifies Transcriptional Regulators of Early Human Embryonic Development.
Hasegawa Y, Taylor D, Ovchinnikov DA, Wolvetang EJ, de Torrenté L, Mar JC., Free PMC Article | 07/23/2018 |
| Molecular chaperone SET-assisted eviction of linker histones and Shugoshins is a fundamental step in mammalian mitotic progression. | Phospho-H1 Decorates the Inter-chromatid Axis and Is Evicted along with Shugoshin by SET during Mitosis.
Krishnan S, Smits AH, Vermeulen M, Reinberg D., Free PMC Article | 09/30/2017 |
| In mouse, Sgol2a encoding shugoshin-like 2a is necessary during meiosis in both sexes to maintain the integrity of the cohesin complex that tethers sister chromatids. Human SGO2 has not previously been implicated in any disorder, but in this case of POI and perhaps others, it is a candidate for unexplained infertility | Mutations of SGO2 and CLDN14 collectively cause coincidental Perrault syndrome.
Faridi R, Rehman AU, Morell RJ, Friedman PL, Demain L, Zahra S, Khan AA, Tohlob D, Assir MZ, Beaman G, Khan SN, Newman WG, Riazuddin S, Friedman TB., Free PMC Article | 07/1/2017 |
| Sgol2's ability to protect cohesin depends on its interaction with PP2A, as is its ability to silence the SAC, with the latter being mediated by direct binding to Mad2 | Sgol2 provides a regulatory platform that coordinates essential cell cycle processes during meiosis I in oocytes.
Rattani A, Wolna M, Ploquin M, Helmhart W, Morrone S, Mayer B, Godwin J, Xu W, Stemmann O, Pendas A, Nasmyth K., Free PMC Article | 03/7/2015 |
| identified the phosphorylation of hSgo2 by Aurora B at the N-terminal coiled-coil region and the middle region, and showed that these phosphorylations separately promote binding of hSgo2 to PP2A and MCAK | Phosphorylation of mammalian Sgo2 by Aurora B recruits PP2A and MCAK to centromeres.
Tanno Y, Kitajima TS, Honda T, Ando Y, Ishiguro K, Watanabe Y., Free PMC Article | 10/23/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR, CPNDS Consortium. | 12/2/2009 |